‘Agile’ Approach Aims To Accelerate Ridgeback’s COVID-19 Timeline

UK Leading On Innovative Adaptive Trials

 
• By Andrew McConaghie

The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.

Liverpool School Of Topical Medicine Accelerator at Royal Liverpool University Hospital
The Liverpool School of Tropical Medicine Accelerator at Royal Liverpool University Hospital is part of the AGILE partnership • Source: AGILE trial

More from Business

More from Scrip